Drug Profile
ISA 101
Alternative Names: HPV-16; HPV-SLP; HPV16-SLP; Human papilloma virus type 16 E6/E7 synthetic long peptides - ISA Pharmaceuticals; ISA 101b; ISA-101; ISA-HPV; ISA-HPV-01; ISA-HPV-SLP®; SLP-HPV-01Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator ISA Pharmaceuticals
- Developer Bristol-Myers Squibb; ISA Pharmaceuticals; Regeneron Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cervical cancer; Head and neck cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer; Vulvar intraepithelial neoplasia
- Phase I/II Anal intraepithelial neoplasia
Most Recent Events
- 12 Dec 2023 Efficacy and adverse events data from a phase II trial in Oropharyngeal cancer was released by ISA Pharmaceuticals
- 12 Dec 2023 ISA Pharmaceuticals plans a confirmatory phase III trial for Oropharyngeal cancer
- 06 Jun 2023 Efficacy and adverse events data from a phase II trial in Squamous cell cancer released by ISA Pharmaceuticals